Therapy of post-renal transplantation hyperlipidaemia: Comparative study with simvastatin and fish oil

Nephrology Dialysis Transplantation

Volumn 12, Issue 10, 1997, Pages 2140-2143

  Castro, R ^a   Queiros J ^a   Fonseca, I ^a   Pimentel, J P S ^a   Henriques, A C ^a   Sarmento, A M ^a   Guimaraes S ^a   Pereira, M C ^a  

^a HOSPITAL DE SANTO ANTÓNIO   (Portugal)

Author keywords

Fish oil; Hyperlipidaemia; Renal transplantation; Simvastatin

Indexed keywords

APOLIPOPROTEIN A1; APOLIPOPROTEIN B; CHOLESTEROL; FISH OIL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LIPOPROTEIN A; LOW DENSITY LIPOPROTEIN CHOLESTEROL; SIMVASTATIN;

ADULT; ARTICLE; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; FEMALE; HUMAN; HYPERLIPIDEMIA; KIDNEY TRANSPLANTATION; LOW FAT DIET; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

ADULT; ANTILIPEMIC AGENTS; FEMALE; FISH OILS; HUMANS; HYPERLIPIDEMIAS; KIDNEY TRANSPLANTATION; LIPIDS; MALE; MIDDLE AGED; POSTOPERATIVE COMPLICATIONS; SIMVASTATIN; TREATMENT OUTCOME;

EID: 0030864444     PISSN: 09310509     EISSN: None     Source Type: Journal    
DOI: 10.1093/ndt/12.10.2140     Document Type: Article

References (30)

1. Drueke TB, Abdulmassih Z, Lacour B et al. Atherosclerosis and lipid disorders after renal transplantation. Kidney Int 1991; 39: S24-S28
2. Wing AJ, Brunner FP, Brynger H et al. Cardiovascular related causes of death and the fate of patients with renovascular disease. Contr Nephrol 1984; 41: 306
3. Lipid research clinics program: The lipid research clinics coronary primary prevention trial results II. The relationship of reduction in incidence of coronary heart disease to cholesterol lowering. J Am Med Assoc 1984; 251: 365-372
4. Isoniemi H. Hyperlipidaemia after renal transplantation-facts and potential implications. Nephrol Dial Transplant 1995; 10: 457-459
5. Traindl O, Reading S, Franz M et al. Treatment of hyperlipidaemic kidney graft recipients with lovastatin: Effect on LDL-cholesterol and lipoprotein(a). Nephron 1992; 62: 394-398
6. Rehman MA, Al-Sulaimain M, Mousa DH et al. Effects of simvastatin in hyperlipidaemic renal transplant patients receiving cyclosporine. Transplantation 1995; 60: 397-399
7. Phillipson BE, Rothrock DW, Connor WE et al. Reduction of plasma lipids, lipoproteins, and apoproteins by dietary fish oils in patients with hypertriglyceridaemia. N Engl J Med 1985; 312: 1210-1216
8. Hirai A, Terano T, Saito H et al. Eicosapentaenoic acid and platelet function in Japanese. In: Lovenburg W, Yamon Y, eds. Nutritional prevention of cardio-vascular disease. Academic Press, New York: 1984; 231-239
9. Sweny P, Wheeler DC, Lui SF et al. Dietary fish oils slow progression of chronic renal graft failure. Transplant Proc 1989; 19: 390
10. Sweny P, Wheeler DC, Lui SF et al. Dietary fish oil supplements preserve renal function in renal transplant recipients with chronic vascular rejection. Nephrol Dial Transplant 1989; 4: 1070-1075
11. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low density lipoprotein cholesterol in plasma without use of preparative ultracentrifuge. Clin Chem 1972; 18: 499-502
12. Chapman JR. Changing the regimen. Nephrol Dial Transplant 1995; 10[Suppl.1] 11: 51-57
13. Ponticelli C, Barbi GL, Cantaluppi A et al. Lipid disorders in renal transplant recipients. Nephron 1978; 20: 189-195
14. Bagdade J, Albers JJ. Plasma high-density lipoprotein concentration in chronic hemodialysis and renal transplant patients. N Engl J Med; 1977; 296: 1436-1442
15. Chan MK, Ramdial L, Varghese Z et al. Plasma LCAT activities in renal allograft recipients. Clin Chim Acta 1982; 124: 187-193
16. Beaumont JE, Galla JH, Luke RG. Normal serum lipids in renal transplant patients. Lancet 1975; 1: 599-600
17. Norman DJ, Illingworth DR, Munson J et al. Myolysis and acute renal failure in heart transplant recipients receiving lovastatin. N Engl J Med 1988; 318: 46
18. Segaert MF, De Soete C, Vandewiele I, Verbanck J. Drug-interaction-induced rhabdo-myolysis. Nephrol Dial Transplant 1996; 11: 1846-1847
19. Goldberg R, Roth D. Evaluation of fluvastatin in the treatment of hypercholesterolaemia in renal transplant recipients taking cyclosporine. Transplantation 1996; 62: 1559-1564
20. Hricik DE. Posttransplant hyperlipidaemia: The treatment dilemma. Am J Kidney Dis 1994; 23: 766
21. Cheung AK, De Vault GA Jr, Gregory MC. A prospective study on treatment of hyper-cholesterolaemia with lovastatin in renal recipients receiving cyclosporine. J Am Soc Nephrol 1993; 3: 1884
22. Arnadottir M, Eriksson LO, Thysell H, Karkas JD. Plasma concentration profiles of simvastatin 3-hydroxy-3-metylglutaryl-coenzyme A reductase inhibitory activity in kidney transplant recipients with and without ciclosporin. Nephron 1993; 65: 410-413
23. Ayanian JZ, Fuchs CS, Stone RM. Lovastatin and rhabdomyolysis (letter). Am Intern Med 1988; 109: 682
24. Castelao AM, Griñȯ JM, Andrés E, Gilvernet S, Serón D et al. HMGCoA reductase inhibitors Lovastatin and Simvastatin in the treatment of hypercholesterolaemia after renal transplantation. Transplant Proc 1993; 25: 1043-1046
25. Martinez Hernandez BE, Persaud JW, Varghese Z, Moorhead JF. Low-dose simvastatin is safe in hyperlipidaemic renal transplant patients. Nephrol Dial Transplant 1993; 8: 637-641
26. Heide JJH, Bilo HJC, Donker AJM et al. Dietary supplementation with fish oil modifies reserve filtration capacity in postoperative, cyclosporine A-treated renal transplant recipients. Transplant Int 1990; 3: 171-175
27. Roach P, Kambouris A, Trimble R et al. Fish oil downregulates the low density lipoprotein receptor and upregulates the high density lipoprotein receptor of rat liver (abstract). Arteriosclerosis 1987; 7: 533a
28. Davis HR, Bridenstine RT, Vesselinovitch D et al. Fish oil inhibits development of atherosclerosis in rhesus monkeys. Arteriosclerosis 1987; 7: 441-449
29. Thiery J, Armstrong VW, Schleef J et al. Serum lipoprotein Lp(a) concentrations are not influenced by an HMG-CoA-reductase inhibitor. Klin Wochenschr 1988; 66: 462-463
30. Kostner GM, Glavish D, Leopold B et al. HMG-CoA-reductase inhibitors lower LDL-cholesterol without reducing lp(a) levels. Circulation 1989; 80: 1313-1319